221 related articles for article (PubMed ID: 25466504)
21. Association of intratumoral vascular endothelial growth factor expression and clinical outcome for patients with gastrointestinal stromal tumors treated with imatinib mesylate.
McAuliffe JC; Lazar AJ; Yang D; Steinert DM; Qiao W; Thall PF; Raymond AK; Benjamin RS; Trent JC
Clin Cancer Res; 2007 Nov; 13(22 Pt 1):6727-34. PubMed ID: 18006774
[TBL] [Abstract][Full Text] [Related]
22. Long-term follow-up outcome of imatinib mesylate treatment for recurrent and unresectable gastrointestinal stromal tumors.
Saito S; Nakata K; Kajiura S; Ando T; Hosokawa A; Sugiyama T
Digestion; 2013; 87(1):47-52. PubMed ID: 23343969
[TBL] [Abstract][Full Text] [Related]
23. Development and validation of a prognostic nomogram for recurrence-free survival after complete surgical resection of localised primary gastrointestinal stromal tumour: a retrospective analysis.
Gold JS; Gönen M; Gutiérrez A; Broto JM; García-del-Muro X; Smyrk TC; Maki RG; Singer S; Brennan MF; Antonescu CR; Donohue JH; DeMatteo RP
Lancet Oncol; 2009 Nov; 10(11):1045-52. PubMed ID: 19793678
[TBL] [Abstract][Full Text] [Related]
24. Long-term follow-up of patients with GIST undergoing metastasectomy in the era of imatinib -- analysis of prognostic factors (EORTC-STBSG collaborative study).
Bauer S; Rutkowski P; Hohenberger P; Miceli R; Fumagalli E; Siedlecki JA; Nguyen BP; Kerst M; Fiore M; Nyckowski P; Hoiczyk M; Cats A; Casali PG; Treckmann J; van Coevorden F; Gronchi A
Eur J Surg Oncol; 2014 Apr; 40(4):412-9. PubMed ID: 24491288
[TBL] [Abstract][Full Text] [Related]
25. Imatinib mesylate: a molecularly targeted therapy for gastrointestinal stromal tumors.
Eisenberg BL
Oncology (Williston Park); 2003 Nov; 17(11):1615-20; discussion 1620, 1623, 1626 passim. PubMed ID: 14682111
[TBL] [Abstract][Full Text] [Related]
26. [Long-term survival in a case of recurrent gastrointestinal stromal tumor treated with intermittent or low-dose imatinib].
Kurata Y; Takaishi S; Sakuma Y; Iwasaki K; Nimura Y; Tohma T; Kagaya A; Yamamoto Y; Matsubara H
Gan To Kagaku Ryoho; 2014 Mar; 41(3):379-82. PubMed ID: 24743288
[TBL] [Abstract][Full Text] [Related]
27. Management of localized gastrointestinal stromal tumors and adjuvant therapy with imatinib.
López RL; del Muro XG
Anticancer Drugs; 2012 Jun; 23 Suppl():S3-6. PubMed ID: 22739667
[TBL] [Abstract][Full Text] [Related]
28. Resection of focally progressive gastrointestinal stromal tumours resistant to imatinib therapy.
Tse GH; Wong EH; O'Dwyer PJ
Surgeon; 2012 Dec; 10(6):309-13. PubMed ID: 22123434
[TBL] [Abstract][Full Text] [Related]
29. Personalized management: inoperable gastrointestinal stromal tumors.
Bae S; Desai J
Clin Gastroenterol Hepatol; 2014 Jan; 12(1):130-4. PubMed ID: 23981520
[TBL] [Abstract][Full Text] [Related]
30. Cost-effectiveness of 3-years of adjuvant imatinib in gastrointestinal stromal tumors (GIST) in the United States.
Sanon M; Taylor DC; Parthan A; Coombs J; Paolantonio M; Sasane M
J Med Econ; 2013; 16(1):150-9. PubMed ID: 22762291
[TBL] [Abstract][Full Text] [Related]
31. [Application of perioperative imatinib mesylate therapy in initial resectable primary local advanced gastrointestinal stromal tumor at intermediate or high risk].
Li SX; Li ZY; Zhang LH; Bu ZD; Wu AW; Wu XJ; Zong XL; Shan F; Ji X; Ji JF
Zhonghua Wei Chang Wai Ke Za Zhi; 2013 Mar; 16(3):226-9. PubMed ID: 23536340
[TBL] [Abstract][Full Text] [Related]
32. [New prospective on adjuvant treatment for gastrointestinal stromal tumors].
Pan ZZ; Wu XJ
Zhonghua Wei Chang Wai Ke Za Zhi; 2013 Mar; 16(3):212-5. PubMed ID: 23536337
[TBL] [Abstract][Full Text] [Related]
33. Imatinib (Glivec) and gastrointestinal stromal tumours in Nigerians.
Durosinmi MA; Salawu L; Lawal OO; Ojo OS; Alatishe OI; Oyekunle AA; Bolarinwa RA; Adisa AO; Badmos K; Anomneze EE; Ayansanwo AO
Afr J Med Med Sci; 2013 Dec; 42(4):325-32. PubMed ID: 24839736
[TBL] [Abstract][Full Text] [Related]
34. A multi-centre analysis of the impact of updated risk stratification on follow-up of gastric gastro-intestinal stromal tumours in the post-imatinib era.
Reece-Smith AM; MacGoey P; Shah MA; Leeder P; Andrew DR; McCulloch T; Parsons SL
Eur J Surg Oncol; 2012 Jun; 38(6):484-9. PubMed ID: 22342866
[TBL] [Abstract][Full Text] [Related]
35. Post-operative imatinib in patients with intermediate or high risk gastrointestinal stromal tumor.
Li J; Gong JF; Wu AW; Shen L
Eur J Surg Oncol; 2011 Apr; 37(4):319-24. PubMed ID: 21277730
[TBL] [Abstract][Full Text] [Related]
36. Diagnosis, prognosis and treatment of patients with gastrointestinal stromal tumour (GIST) and germline mutation of KIT exon 13.
Bachet JB; Landi B; Laurent-Puig P; Italiano A; Le Cesne A; Lévy P; Safar V; Duffaud F; Blay JY; Emile JF
Eur J Cancer; 2013 Jul; 49(11):2531-41. PubMed ID: 23648119
[TBL] [Abstract][Full Text] [Related]
37. Gastrointestinal stromal tumor: 5 years later.
van der Zwan SM; DeMatteo RP
Cancer; 2005 Nov; 104(9):1781-8. PubMed ID: 16136600
[TBL] [Abstract][Full Text] [Related]
38. Follow-up strategies for patients with gastrointestinal stromal tumour treated with or without adjuvant imatinib after surgery.
Joensuu H; Martin-Broto J; Nishida T; Reichardt P; Schöffski P; Maki RG
Eur J Cancer; 2015 Aug; 51(12):1611-7. PubMed ID: 26022432
[TBL] [Abstract][Full Text] [Related]
39. [Two cases of recurrent GIST successfully treated with imatinib mesylate at 100mg/day].
Hanada N; Kawata K; Okamura S; Tomiyama N; Hori K
Gan To Kagaku Ryoho; 2013 Jun; 40(6):803-5. PubMed ID: 23863663
[TBL] [Abstract][Full Text] [Related]
40. Adherence to imatinib therapy in patients with gastrointestinal stromal tumors.
Blay JY; Rutkowski P
Cancer Treat Rev; 2014 Mar; 40(2):242-7. PubMed ID: 23931926
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]